Key Highlights

  • Scopus BioPharma's last periodic SEC report was a Form 10-Q covering the quarter ended June 30, 2023, with only limited filings since.
  • The company completed a Nasdaq listing in late 2020 before pursuing corporate restructuring and Subsidiary asset transactions.
  • The ticker is no longer present in Nasdaq's list of exchange-listed tickers, consistent with a move to over-the-counter trading.

Few names on U.S. markets illustrate the fragility of early-stage biotech better than Scopus BioPharma, Inc (OTC: SCPS). (SCPS). Once a Nasdaq-listed clinical-stage company pursuing immuno-oncology and genetic-medicine therapies, SCPS now changes hands at a fraction of a cent, and its public filing trail has gone quiet. The gap between the company's former ambitions and its current standing is the real story for anyone typing the ticker into a screener in September 2026 - and it is a cautionary one rather than a catalyst-driven one.

Company and Latest Development

Scopus BioPharma (SEC CIK 1772028) built its identity around developing novel therapeutics, with early programs positioned in immuno-oncology and gene-based medicine. The company completed a Nasdaq listing in late 2020 and, over the following years, pursued corporate restructuring and transactions involving its subsidiary assets. The most important development for investors today, however, is administrative rather than clinical: the company's SEC filing record shows its last periodic report - a Form 10-Q - covering the quarter ended 30 June 2023, followed by only limited filings into early 2024. There is no evidence in the public record of continued regular reporting since.

What Is Driving Attention Around SCPS?

The honest answer is that no single, verifiable public catalyst explains recent trading in SCPS. The stock sits at sub-penny levels with a negligible market value, the kind of Quotation typically associated with dormant or reporting-delinquent shells rather than an operating Business announcing news. Trading in securities like this is frequently driven by illiquidity and speculative flows rather than fundamentals or fresh disclosures. Absent current financial statements, press releases or regulatory milestones, attention around SCPS appears to reflect its status as an ultra-low-priced ticker rather than any confirmed corporate event.

Key Numbers and Company Position

Verified figures are scarce, precisely because the company does not appear to be filing current financials. What can be confirmed from SEC EDGAR is the identity (Scopus BioPharma, Inc.), the CIK, and a filing timeline ending with mid-2023 periodic reporting. The ticker is no longer present in the SEC's list of exchange-listed company tickers, consistent with a move off Nasdaq to over-the-counter trading. Market-data snapshots place the shares at a fraction of a cent with a market Capitalization measured in the low tens of thousands of dollars - figures consistent with a micro-cap that has effectively wound down active operations.

What Could Come Next?

For a company in this posture, the meaningful questions are structural. Investors watching SCPS may look for any resumption of SEC reporting, a Reverse merger or shell-repurposing transaction, a change of control, or formal confirmation of the company's status. Any of these would materially reshape the story. Equally possible is continued dormancy, in which case the quotation could persist without underlying operating activity. None of these outcomes is confirmed, and no timeline has been publicly disclosed.

Risks to Watch

The risks here are acute. Sub-penny, reporting-delinquent stocks carry extreme liquidity risk, wide bid-ask spreads, and the potential for total loss of capital. The absence of current financial statements makes Fundamental Analysis impossible, and OTC micro-caps are especially vulnerable to volatility, dilution and promotional activity. Regulatory actions such as trading suspensions are also a possibility for delinquent filers. This is a speculative situation, not a conventional Investment case.

Conclusion

Scopus BioPharma's story has shifted from clinical ambition to administrative uncertainty. With SEC filings trailing off after mid-2023 and the shares trading at a fraction of a cent, SCPS reads today as a dormant micro-cap rather than an active biotech with pending catalysts. Investors may want to monitor EDGAR for any renewed reporting or corporate transaction, while treating the absence of verifiable, current information as the defining risk. For now, honesty about what cannot be confirmed is the most useful takeaway.